ZBIO: Obexelimab nears FDA review as multiple pipeline assets advance toward key data and regulatory milestones
Multiple late-stage and early pipeline programs are advancing, with obexelimab under FDA review and key data readouts expected for SLE and MS programs. Commercial infrastructure is in place, and filings in Europe are planned. AI is being adopted for business efficiency, with several clinical and re…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.